Cephalothin

CHEMBL617 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
396.4 g/mol
LogP
-0.4
Phase
4

A first-generation parenteral cephalosporin antibiotic that inhibits cell wall synthesis, historically used for gram-positive infections including staphylococcal infections before the emergence of MRSA. It was one of the first cephalosporins available but is now largely obsolete in clinical practice. It has been replaced by safer and more effective agents.

الوزن الجزيئي

396,4000 g/mol

LogP

-0,40

TPSA

167,00 Ų

قاعدة ليبينسكي للخمسة

ناجح

آلية العمل

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3cccs3)[C@H]2SC1

InChI

InChI=1S/C16H16N2O6S2/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23)/t12-,15-/m1/s1

Molecular Formula

C16H16N2O6S2

HBD / HBA

2 / 8

الروابط القابلة للدوران

7

الذرات الثقيلة

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A first-generation parenteral cephalosporin antibiotic that inhibits cell wall synthesis, historically used for gram-positive infections including staphylococcal infections before the emergence of MRSA. It was one of the first cephalosporins available but is now largely obsolete in clinical practice. It has been replaced by safer and more effective agents.

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Yes, Cephalothin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL617. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6024. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.